LAVA Therapeutics (NASDAQ:LVTX) Short Interest Up 695.8% in October

LAVA Therapeutics (NASDAQ:LVTX) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 19,100 shares, a growth of 695.8% from the October 15th total of 2,400 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 49,600 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of LAVA Therapeutics

An institutional investor recently bought a new position in LAVA Therapeutics stock. XTX Topco Ltd bought a new stake in LAVA Therapeutics (NASDAQ:LVTX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 30,807 shares of the company’s stock, valued at approximately $55,000. XTX Topco Ltd owned about 0.12% of LAVA Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Analyst Ratings Changes

Separately, JMP Securities restated a “market outperform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, August 21st.

LAVA Therapeutics Stock Down 4.9 %

Shares of LVTX traded down $0.09 during midday trading on Tuesday, hitting $1.76. 22,775 shares of the company’s stock traded hands, compared to its average volume of 568,679. LAVA Therapeutics has a 1 year low of $1.35 and a 1 year high of $6.47. The firm’s fifty day moving average is $1.73 and its 200-day moving average is $2.03. The company has a current ratio of 6.39, a quick ratio of 6.39 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $44.62 million, a price-to-earnings ratio of -2.03 and a beta of 0.49.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings data on Tuesday, August 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative return on equity of 48.53% and a negative net margin of 228.02%. As a group, sell-side analysts anticipate that LAVA Therapeutics will post -1.28 earnings per share for the current year.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.